Janus kinase 1 inhibitor INCB054707 for patients with moderate‐to‐severe hidradenitis suppurativa: results from two phase II studies

BACKGROUND: Janus kinase (JAK)‐mediated cytokine signalling contributes to local and systemic inflammation in hidradenitis suppurativa (HS). OBJECTIVES: To describe the safety and efficacy results from two multicentre phase II trials of the JAK1 inhibitor INCB054707 in patients with moderate‐to‐seve...

Descripción completa

Detalles Bibliográficos
Autores principales: Alavi, Afsaneh, Hamzavi, Iltefat, Brown, Kurt, Santos, Leandro L., Zhu, Zhaoyin, Liu, Huiqing, Howell, Michael D., Kirby, Joslyn S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314604/
https://www.ncbi.nlm.nih.gov/pubmed/34978076
http://dx.doi.org/10.1111/bjd.20969

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314604/
https://www.ncbi.nlm.nih.gov/pubmed/34978076
http://dx.doi.org/10.1111/bjd.20969

Ejemplares similares